Mativ (NYSE:MATV – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.26 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Mativ (NYSE:MATV – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.13. Mativ had a positive return on equity of 5.19% and a negative net margin of 16.55%. The company had revenue of $523.80 million during the quarter, compared to the consensus estimate of $526.50 million. During the same period in the prior year, the company earned $0.51 earnings per share. On average, analysts expect Mativ to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Mativ Stock Up 0.4 %
Shares of Mativ stock opened at $15.66 on Tuesday. Mativ has a 1 year low of $10.78 and a 1 year high of $19.96. The business has a 50-day moving average of $17.11 and a two-hundred day moving average of $17.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.33 and a current ratio of 2.46.
Mativ Announces Dividend
Mativ Company Profile
Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.
Further Reading
- Five stocks we like better than Mativ
- What is the S&P 500 and How It is Distinct from Other Indexes
- Intel: Is Now the Time to Be Brave?
- Best Aerospace Stocks Investing
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Mativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mativ and related companies with MarketBeat.com's FREE daily email newsletter.